Introduction {#Sec1}
============

Chronic inflammatory conditions such as rheumatoid arthritis are manifestations of inappropriate immune responses, where activation and regulation are imbalanced.

Anti-inflammatory agents such as TNF-α antagonists can achieve significant results; however, a subset of patients do not respond. The current absence of clinically useful predictors of response continues to impact both the clinical management of patients and associated treatment costs.

The KIR gene cluster, located on chromosome 19q13.4 \[[@CR1]\], codes for a family of polymorphic receptors which can be activating (KIR2DS/KIR3DS) or inhibiting (KIR2DL/KIR3DL) in function. KIR are expressed on natural killer (NK) cells and subsets of T-cells and modulate cell responses through recognition of human leukocyte antigen (HLA) class I ligands on target cells.

Under normal conditions, inhibitory receptors KIR2DL2 and KIR2DL3 recognize self-HLA-C1 ligands and KIR2DL1 binds HLA-C2 ligands, acting to prevent NK cell attack on normal cells. In the absence of these inhibiting KIR-HLA signals, NK cell activation may occur through activating receptors such as KIR2DS1 and KIR2DS2 \[[@CR2], [@CR3]\]. It is the net balance of activating and inhibiting signals from receptors such as KIR that determine NK cell and T-cell reactivity. An individual's genotype predisposes to specific KIR/HLA interactions, which may range from activating to relatively inhibitory depending on which type of KIR and HLA is present \[[@CR4]\].

Specific KIR-HLA combinations have been associated with differential responses to infection \[[@CR5]--[@CR7]\] and susceptibility to autoimmune disorders including Crohn's disease \[[@CR8]--[@CR10]\], ulcerative colitis \[[@CR10], [@CR11]\], systemic lupus erythematosus \[[@CR12], [@CR13]\], type I diabetes \[[@CR14]\], and psoriatic arthritis \[[@CR15]\]. In the case of autoimmunity, the presence of an activating KIR and/or absence of ligands for inhibitory KIR is commonly associated with disease susceptibility.

In RA, activating KIR2DS2 has been shown to function as a co-stimulatory molecule on CD4^+^CD28^null^ T-cells \[[@CR16]\]. The expansion of this subset correlates with the clinical phenotype of RA, where KIR2DS2 has been associated with an increased likelihood for RA patients to develop rheumatoid vasculitis \[[@CR17]--[@CR19]\].

These studies suggest a role for KIR in determining the immune response in inflammatory disease, which prompts the question of whether a particular KIR predisposition could also influence response to anti-inflammatory treatment.

In this study, we examined the KIR and HLA-C genotypes of RA patients beginning anti-TNF-α treatment and healthy controls. We found that the presence of *KIR2DS2/KIR2DL2* was significantly associated with patients who responded to therapy. Further consideration of KIR with HLA-C ligand availability indicated a potentially activating KIR--HLA-C genotype in responding patients relative to non-responders to anti-TNF-α therapy.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Sixty-four unrelated Northern Irish chronic RA patients were included in this study. Each subject was a patient attending the rheumatology department of Musgrave Park Hospital, Belfast, Northern Ireland. All patients fulfilled the American College of Rheumatology 1987 revised criteria for RA \[[@CR20]\] and had active disease as indicated by a DAS28 score of \>3.2 \[[@CR21]\].

There was no significant difference between the responding and non-responding patients with respect to the distribution of age (*P* = 0.21, unequal variance two-sided *t*-test) or sex (*P* = 0.74, two-sided Fishers' exact test).

Patients were assigned to anti-TNF-α treatment as part of routine clinical practice. Each patient fulfilled the British Society for Rheumatology (BSR) criteria for anti-TNF-α therapy and had failed at least two disease-modifying anti-rheumatic drugs (DMARDS) and had a DAS28 score of \>5.1 when originally assessed for treatment \[[@CR22]\]. In some cases, DAS28 scores between original assessment and baseline treatment fluctuated, due to time lapsed from assessment to treatment. Forty patients received adalimumab, 15 etanercept, and 9 infliximab. In most cases, methotrexate (MTX) was maintained as a combination therapy, and patients were allowed to continue oral glucocorticoids. The main demographic and clinical features of the patients are shown in Table [1](#Tab1){ref-type="table"}. Thirty-eight patients received a combination of MTX and anti-TNF-α drugs (adalimumab, etanercept, or infliximab). There exists no significant correlation between the anti-TNF-α drug and the treatment outcome in those patients who received MTX (*P* = 0.35, χ^2^-test). In the group of patients who did not receive MTX, we observed relatively more patients responding to etanercept than to adalimumab (7 R and 1 NR vs. 8 R and 10 NR, *P* = 0.08, Fisher's exact test).Table 1Demographic and clinical characteristics of patientsRespondersNon-respondersAllTotal343064Mean age (years)58 (range, 35--75)54.53 (range, 27--73)56.33 (range, 27--75)Woman/man28/626/454/10MTX and adalimumab91322MTX and etanercept527MTX and infliximab549Adalimumab81018Etanercept718Infliximab000Mean pre-DAS28 score6.21 (range, 4.08--8.96)5.43 (range, 3.75--7.38)5.85 (range, 3.75--8.96)Mean post-DAS28 score3.64 (range, 1.18--6.15)5.61 (range, 3.49--7.27)4.53 (range, 1.18--7.27)

Peripheral blood samples were collected from each patient at time 0. Following 3 months of treatment, the patients were assigned a responder or non-responder status, according to the BSR criterion where clinical response is defined as attaining a DAS28 score improvement of \>1.2 or a DAS28 score of \<3.2 \[[@CR22]\].

A control population of 100 unrelated healthy Northern Irish Caucasians were included for comparison of KIR gene content. The healthy control blood samples were collected at Northern Ireland Blood Transfusion Services, Belfast. All participants in the study gave written informed consent, and the study had local research ethical committee approval from The Queens University, Belfast, Northern Ireland.

Genotyping {#Sec4}
----------

Genomic DNA was extracted from peripheral blood lymphocytes using the salting-out method as previously described \[[@CR23]\]. DNA was typed for the presence or absence of framework KIR genes: *KIR2DL4*, *KIR3DL2*, *KIR3DL3*, and *KIR3DP1*, six activatory KIR (*KIR2DS1, KIR2DS2, KIR2S3, KIR2DS4, KIR2DS5* and *KIR3DS1*) and five inhibitory KIR (*KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, KIR2DL5*). *KIR2DP1* was also included in the typing. KIR genotyping was performed using the PCR primers and probes of a KIR PCR-SSOP method \[[@CR24]\]. Positive controls of known KIR genotype, collectively incorporating all of the KIR genes, were included in the typing procedure.

HLA-C typing was performed using the PCR-SSOP method. DNA was amplified by PCR using the HLA-C generic primers described by Cereb et al*.* \[[@CR25]\]. A modified version of the HLA-C typing method was used to define the HLA-C1 and C2 groups using probe C293 and C291, respectively \[[@CR26]\].

Statistical methods and analysis {#Sec5}
--------------------------------

The significance of the differences in proportions of responders and non-responders exhibiting a specific genotype was assessed using Fisher's exact test. Welch's *t*-statistics and paired *t*-tests were used to investigate differences in the DAS28 score. All tests were two-sided unless otherwise stated. Adjustments for multiple testing were made using Holm's method.

Results {#Sec6}
=======

Within the group of 64 patients (described in Table [1](#Tab1){ref-type="table"}), 34 were responders (53.0%) and 30 were non-responders (47.0%). We compared the profiles of the KIR genes in the groups of responders and non-responders to anti-TNF-α therapy. In the responder population, the frequency of *KIR2DS2* and *KIR2DL2* (which share high linkage disequilibrium) was significantly higher compared with non-responders (67.7% vs. 33.3%; *P* = 0.012, Fisher's exact test). To assess the relevance of the *P*-value and to reduce the effect of multiple comparisons arising from testing a family of 16 KIR genes, we performed a non-parametric random permutation test as follows \[[@CR27]\]. We randomly permuted the class labels of all 64 patients and recomputed the *P*-value for the difference in proportions of carriers/non-carriers in responders and non-responders. We iterated this procedure 10,000 times to generate the distribution of *P*-values under the null hypothesis of no association between the presence/absence of *KIR2DS2/KIR2DL2* and response to therapy. Among 100,000 permutation-based *P*-values, only 1.17% are smaller than or equal to the unpermuted *P*-value of 0.012. This confirms that carriership of *KIR2DS2/KIR2L2* and the response to therapy cannot be explained by chance alone.

There was no significant difference between the baseline DAS28 score of patients carrying *KIR2DS2/KIR2DL2* and those who did not (*P* = 0.57, two-sided, unequal variance *t*-test). The drug regime improved the DAS28 score in both carriers (*P* = 0.005, paired *t*-test) and non-carriers of *KIR2DS2/KIR2DL2* (*P* \< 1.6 × 10^−6^, paired *t*-test). This improvement, however, was significantly larger in patients carrying *KIR2DS2/KIR2DL2* (*P* = 0.04, two-sided, unequal variance *t*-test).

When compared with healthy controls, the *KIR2DS2/KIR2DL2*-positive genotype remained significantly more frequent in the responder group (67.6% responders vs. 40.0% controls, *P* = 0.009). However, carriership of *KIR2DS2/KIR2DL2* in the non-responders was not significantly different to healthy controls. The frequencies of all other KIR genes tested were not significantly different between responders, non-responders, or the healthy control groups.

To consider the additional effect of *HLA*-*C* zygosity, patients were categorized into four groups similar to a psoriatic arthritis model proposed by Nelson et al*.* \[[@CR15]\]. The genotype groups range from NK cell activating (group I) to inhibiting (group IV) based on KIR-HLA interactions. Nelson's model considered the presence/absence of both *KIR2DS1* and *KIR2DS2* with HLA-C zygosity. However, since *KIR2DS1* was not informative in our study, we modified Nelson's model to consider only *KIR2DS2* in our interpretation. Thus, the most activating genotype, group I, included patients who were positive for activating *KIR2DS2* and were *HLA*-*C* homozygous (C1/C1 or C2/C2). Such *HLA*-*C* homozygosity limits ligand availability for inhibitory KIR (*KIR2DL1* or *KIR2DL2/KIR2L3*), restricting counteracting inhibition signals. Patients in group II were *KIR2DS2* positive and were *HLA*-*C* heterozygous (i.e., they had both ligands C1/C2 and therefore relatively more inhibitory receptor functionality due to ligand availability). Group III patients were *KIR2DS2* negative and *HLA*-*C* homozygous (without the activating receptor *KIR2DS2* but limited inhibitory function through homozygosity for the HLA-C ligands of inhibitory KIR). Finally, the most inhibitory genotype group IV patients were *KIR2DS2* negative and *HLA*-*C* heterozygous. Group IV patients are predisposed to a more inhibiting genotype since they lack *KIR2DS2* and carry both HLA-C ligand types, promoting function of all corresponding inhibitory KIR receptors.

We observed that the ratio of responders to non-responders inverts from groups I to IV (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Number of responders (*white*) and non-responders (*black*) in the groups I to IV. Groups range from most activating to most inhibiting from groups I to IV, respectively. Patients included in group I are *KIR2DS2* positive and *HLA*-*C* group 1/2 homozygous (C1/C1 or C2/C2). Group II patients are *KIR2DS2* positive and *HLA*-*C* group 1/2 heterozygous (C1/C2). Group III patients are *KIR2DS2* negative and *HLA*-*C* group 1/2 homozygous. Group IV patients are *KIR2DS2* negative and *HLA*-*C* group 1/2 hetrozygous

A groupwise comparison of the number of responders and non-responders revealed a significant difference between groups I and IV (*P* = 0.015, adjusted for multiple comparisons using Holm's correction). No other groupwise comparison revealed a significant difference.

There was no significant difference between the groups with respect to the DAS28 score before therapy. The majority of patients in groups I to III experienced a significant reduction in the DAS28 score after treatment (*P* = 0.004, *P* = 0.004, and *P* = 0.033, respectively, based on paired *t*-test with Holm's correction), whereas patients in group IV did not (*P* = 0.161). Table [2](#Tab2){ref-type="table"} summarizes the DAS28 scores at baseline, 3 months after therapy, and the improvements in groups I and IV. The mean DAS28 score improvement for patients in group I was significantly larger than that of group IV (*P* = 0.022).Table 2Patient disease activity scores according to KIR and HLA-C genotype statusGroup I (2DS2^+^HLA-C homo)Group IV (2DS2^−^HLA-C hetero)DAS28 at baseline6.05 (range, 4.28--8.96)5.64 (range, 3.75--7.38)DAS28 after 3 months4.25 (range, 2.11--7.27)5.16 (range, 1.95--7.22)DAS28 improvement1.80 (range, −1.85 to 3.92)0.48 (range, −2.25 to 3.32)\# responders/non-responders13/35/13*P*-value of improvement0.0040.161Group I: *KIR2DS2* positive and *HLA*-*C* homozygous (C1/C1 or C2/C2), Group IV: *KIR2DS2* negative and *HLA*-*C* heterozygous (C1/C2)

These results suggest that there exist subgroups of patients characterized by distinct KIR and HLA-C genotype profiles that are associated with a significant difference of response to anti-TNF-α therapy.

Discussion {#Sec7}
==========

The influence of the KIR genes in inflammatory disease is supported by a growing body of evidence demonstrating the association of specific KIR genotypes with disease.

Further consideration of the cumulative effect of KIR with HLA ligand availability permits differentiation of subjects to relatively activating or inhibiting genotypes, which ultimately influence the responses of KIR-expressing cells.

The promotion or prevention of NK cell activation crucially influences innate defences, the facilitation of cross talk between cells, and adaptive immunity. NK cell importance in immune regulation is reflected through their interaction with components of the adaptive immune system where they have been shown to eradicate autoreactive T-cells and B-cells \[[@CR28]\].

In this study, a KIR-HLA combination that favors NK cell activation through the presence of activating *KIR2DS2* and homozygosity for *HLA*-*C1* or *HLA*-*C2* was associated with responders to anti-TNF-α. Historically, NK cell activity in the peripheral blood of RA patients has been reported to be normal \[[@CR29], [@CR30]\] or low \[[@CR31]--[@CR33]\]. It is possible that responders could have a different mechanism of disease pathogenesis than non-responders, and it would be interesting to investigate NK cell activity in both groups. The occurrence of an inhibitory profile of NK cells in non-responders is supported by their prevalence in the proposed group IV cohort that are *KIR2DS2* negative and *HLA*-*C* heterozygous. The general inversion of the numbers of responders and non-responders moving through groups I to IV, perhaps speaks to the continuum of excellent to poor responders observed in clinical practice. In this model, determination of where those patients who gain responses from up-dosing or switching anti-TNF-α therapy are positioned would also be of interest.

Our study has several limitations that impact the interpretation of these findings. In this small cohort of 64 subjects, we provide preliminary data suggesting a possible role for a KIR--HLA-C genotype in response to anti-TNF-α therapy. These findings will require independent validation in a larger population, which will permit further sub-analysis of KIR--HLA-C genotype and response for each anti-TNF-α therapy.

*KIR2DS2* has been associated with vascular complications of RA \[[@CR16], [@CR18], [@CR19]\] and with numerous inflammatory conditions and autoimmune outcomes \[[@CR11], [@CR13]--[@CR15], [@CR34], [@CR35]\]. It is therefore not surprising that this activating KIR is implemented in response to anti-inflammatory therapy. It could be argued that patients carrying *KIR2DS2* may be subject to a greater disease severity and hence are likely to show a more robust response to therapy. In this study, the baseline DAS28 scores of responders were significantly higher than those of non-responders, but this could not be attributed to carriership of *KIR2DS2*. The baseline DAS28 scores for patients with and without *KIR2DS2* were not statistically different; however, the improvement of the score was significantly larger in the group of patients carrying this gene.

In previous reports, inflammatory cytokine polymorphisms such as TNF-α --308G/A have indicated that a genetic predisposition toward increased TNF-α expression can be associated with non-response \[[@CR36]--[@CR39]\], These findings have been disputed in a recent meta-analysis by Pavy et al. \[[@CR40]\], and so, the role of this SNP remains unclear.

A gene expression study of baseline synovial tissue indicated an upregulation of inflammation-related genes in patients who responded to infliximab \[[@CR41]\]. In proteomics, a baseline 24-protein signature of elevated serum antibody and cytokine concentrations is reported in RA patients who responded to etanercept \[[@CR42]\]. Alternatively, Badot et al*.* \[[@CR43]\] related non-responders to adalimumab with overexpression of cell division and immune regulation genes.

These studies and our current study point to a possible activating profile that may provide an advantage for response to anti-TNF-α therapy.
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